文献速递流行病学与生物统计临床试验与 GCP

评估持续再评估方法性能的无模拟方法

A simulation-free approach to assessing the performance of the continual reassessment method.
PubMed 文献 · Stat Med · 2020-09-16

针对I期试验的持续再评估方法(CRM),其操作特性通常需通过模拟评估,耗时数小时至数天。作者基于CRM的一致性,提出用单次模拟替代数千次假设试验的模拟研究,能准确反映模拟结果且大幅缩短时间,并给出非一致性度量与维持一致性的算法。

要点

  • 基于CRM一致性的单次模拟可替代传统大规模模拟评估操作特性。
  • 该方法能准确反映模拟研究结果,但所需时间仅为模拟研究的一小部分。
  • 非一致性可影响方法性能且高估或低估程度不可预测,需用算法维持设计一致性。

核心结论

  • 基于CRM一致性的单次模拟方法能非常准确地反映传统模拟研究的结果,且耗时仅为后者的一小部分。

研究设计与样本

  • 方法学研究:针对给定的真实DLT概率向量,用单次模拟替代数千次假设试验的模拟研究。
  • 以基于已发表I期试验特征的假设试验为例,广泛检验该方法评估CRM设计操作特性的能力。

主要发现

  • 该方法能非常准确地反映模拟研究产生的结果,但耗时仅为模拟研究所需时间的一小部分。
  • 非一致性可影响该方法的操作特性,且高估或低估的程度不可预测。

关键数值与推荐

  • 原文未报告具体数值、比例、阈值、样本量或P值。

临床怎么用

  • 在I期CRM设计评估中,可用基于一致性的单次模拟快速评估操作特性,替代耗时数小时至数天的传统模拟。
  • 应用前需采用作者提供的算法维持所选CRM设计的一致性,以保障方法适用性。

局限性

  • 非一致性可影响该方法操作特性,且高估或低估程度不可预测。
  • 方法适用性依赖于所选CRM设计的一致性,需通过算法维持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The continual reassessment method (CRM) is an adaptive design for Phase I trials whose operating characteristics, including appropriate sample size, probability of correctly identifying the maximum tolerated dose, and the expected proportion of participants assigned to each dose, can only be determined via simulation. The actual time to determine a final "best" design can take several hours or days, depending on the number of scenarios that are examined. The computational cost increases as the kernel of the one-parameter CRM design is expanded to other settings, including additional parameters, monitoring of both toxicity and efficacy, and studies of combinations of two agents. For a given vector of true DLT probabilities, we have developed an approach that replaces a simulation study of thousands of hypothetical trials with a single simulation. Our approach, which is founded on the consistency of the CRM, very accurately reflects the results produced by the simulation study, but does so in a fraction of time required by the simulation study. Relative to traditional simulations, we extensively examine how our method is able to assess the operating characteristics of a CRM design for a hypothetical trial whose characteristics are based upon a previously published Phase I trial. We also provide a metric of nonconsistency and demonstrate that although nonconsistency can impact the operating characteristics of our method, the degree of over- or under-estimation is unpredictable. As a solution, we provide an algorithm for maintaining the consistency of a chosen CRM design so that our method is applicable for any trial.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Braun TM. A simulation-free approach to assessing the performance of the continual reassessment method. Stat Med. 2020. PMID: 32939800. doi:10.1002/sim.8746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。